Key points: GLP-1 use: More patients are presenting for procedures while taking GLP-1RAs for diabetes or weight loss Main concern: GLP-1RAs can delay gastric emptying, which may increase aspiration risk during sedation Continue therapy: Current guidance supports continuing GLP-1RAs in patients without significant aspiration risk, using shared decision-making Assess risk factors: Recent start or dose escalation, weekly/high-dose therapy, GI symptoms, gastroparesis or other motility disorders Key takeaway: Most interventional pain procedures can be performed safely with local anesthetic alone, making conscious sedation unnecessary in many cases Conclusion: This study highlights the importance of individualized risk assessment and avoiding unnecessary sedation to improve safety in patients taking GLP-1RAs
If a medication reduces appetite, causes nausea, makes hydration difficult, or leads to rapid weight change, your body may have less energy available during a demanding lactation season
The changes in digestion and appetite mean that every food choice carries more weight, impacting both your comfort and your progress
Calibrate emphasizes a dedicated physician relationship at onboarding with ongoing async messaging
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the hormones released in our bodies when we eat
Individuals who are able to stick to a healthy diet and exercise program while using semaglutide are typically the ones who see the best results